http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005226919-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a7f54c55c0e4c47914268412af8f8ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21c1c987c561d09f679d2b2ddbe61349 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_64f2ec10fa0b5d1d303ec269193ab1ac |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-70 |
| filingDate | 2002-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_835a968ea473d934ee2e505e7444a623 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe3d3a435a25acbd6f779ba44c8cb5a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23b126e7d60323c557e52fb421a2b89c |
| publicationDate | 2005-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2005226919-A1 |
| titleOfInvention | Device for transdermal administration for the treatment of urinary tract disorders |
| abstract | This invention provides a device containing a compound of formula (I), wherein R represents a saturated or unsaturated C 2-7 aliphatic acyl group optionally substituted by one or more halogen atoms, a hydroxy group, a C 1-6 alkoxy group, a carboxyl group, a C 2-7 alkoxycarbonyl group, a 5 to 7-membered cycloalkyl group, a phenyl or naphthyl group; a C 2-6 hydroxyalkyl group; an aliphatic acyloxyalkyl group having a C 2-7 acyl group and a C 1-6 alkyl group; a C 1-6 alkyl group substituted by a C 1-6 alkoxy group, a carboxyl group, a C 2-7 alkoxycarbonyl group, a C 2-7 alkoxycarbonyl group substituted by a phenyl or naphthyl group, a carbamoyl group, a mono- or di-(C 1-6 alkyl)-substituted carbamoyl group or a cyano group; a benzoyl or naphthoyl group optionally substituted by one or more halogen atoms; a furoyl group or a pyridylcarbonyl group; and R 1 represents a C 1-6 alkyl group optionally substituted by one or more halogen atoms, a phenyl or a naphthyl group; the carbon atom marked “*” represents a carbon atom in (R)-configuration, (S)-configuration or a mixture thereof. The TTS is efficient in the treatment of urinary tract disorders, such as benign prostatic hypertrophy. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006292210-A1 |
| priorityDate | 2001-09-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 233.